Anti-GAD65 Antibodies Related Refractory Epilepsy Successfully Treated with Tocilizumab: A Case Report and Systematic Literature Review
Tocilizumab seems to be an effective therapy for the refractory anti-GAD65 related epilepsy as it can control seizures, improve cognition and neuropsychiatric symptoms.
Authors
- Miriam Kessi (ORCID: https://orcid.org/0000-0002-7932-9292)
- Jing Peng (ORCID: https://orcid.org/0000-0002-7752-6962)
- Ciliu Zhang (ORCID: https://orcid.org/0000-0002-2230-9047)
- Fei Yin (ORCID: https://orcid.org/0000-0002-7192-6308)
- Lifen Yang (ORCID: https://orcid.org/0000-0003-2400-9539)
- Fang He (ORCID: https://orcid.org/0000-0002-7627-0424)
- Jie-lu Tan
- Shimeng Chen (ORCID: https://orcid.org/0000-0002-5255-8992)
Institutions
- Central South University (CN)
- Hunan Provincial People's Hospital (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/itt.s520026
- Citations
- 4
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.56